Loading company
Fennec Pharmaceuticals Inc.
FENC · Nasdaq · ·
$10.78-1.7%Sep 29 close
- 1M
- -12.1%
- 6M
- +86.8%
- 1Y
- +15.2%
- 5Y
- +15.3%
FENC · Nasdaq · ·
$10.78-1.7%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $17.9M | $9.7M | +85.18% |
| Profit | $2M | -$3.2M | +162.60% |
| Profit per share | $0.05 | -$0.11 | +145.45% |
| Free Cash Flow | -$443K | -$469K | +5.54% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Fennec Pharmaceuticals Inc. has no earnings call transcript available.
“Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec into its next chapter of growth. We delivered record net product sales, achieved significant growth within our Fennec HEARS ® program, and advanced independent clinical evidence generation for PEDMARK ® – all while driving quarter-over-quarter growth in every quarter in 2025. These results demonstrate increasing PEDMARK ® adoption across key accounts and patient segments, effective field execution, and sustained progress across the organization ,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK ® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI Ò . In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Fennec Pharmaceuticals Inc.’s Item 2.02 8-K filed March 24, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.